To counteract tryptophan depletion, IDO1 inhibitors (such as epacadostat and linrodostat) are being evaluated in combination with PD-1 blockade to restore T-cell metabolic fitness and enhance antitumor efficacy in NSCLC. The gene discussed is IDO1; the disease is non-small cell lung carcinoma.